bit.bio raises $25M Series D as demand for its human cell models grows
Open the sourceReported by The Next Web, thenextweb.com, 4 November 2026, by Ana-Maria Stanciuc
45Impact 45 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at thenextweb.com.
Named in this story
bit.bio, Jonathan Milner, M&G Investments, Abcam, Cambridge